Apixaban Dosing Equivalent to Therapeutic LMWH and VTE Prophylaxis
For VTE treatment, apixaban 10 mg twice daily for 7 days followed by 5 mg twice daily is the therapeutic equivalent to LMWH (enoxaparin 1 mg/kg twice daily or dalteparin 200 IU/kg daily), while for VTE prophylaxis, apixaban 2.5 mg twice daily is used post-orthopedic surgery. 1
VTE Treatment Dosing
Standard Therapeutic Dosing
- Apixaban: 10 mg orally twice daily for 7 days, then 5 mg twice daily 1
- LMWH equivalent:
Key advantage: Apixaban requires no initial parenteral anticoagulation, unlike dabigatran or edoxaban which require 5-10 days of LMWH bridging 4
Extended/Secondary Prophylaxis (After ≥6 months of treatment)
- Apixaban: 2.5 mg twice daily 1
- This lower dose is specifically for recurrence prevention after completing initial treatment phase 4
VTE Prophylaxis Dosing
Post-Orthopedic Surgery
- Apixaban: 2.5 mg twice daily starting 12-24 hours post-surgery 1
- Hip replacement: 35 days duration
- Knee replacement: 12 days duration
- LMWH equivalent:
Dose Adjustments for Special Populations
Renal Impairment
Critical consideration: Apixaban has minimal renal clearance compared to LMWH, making it advantageous in renal dysfunction 4, 5
CrCl <30 mL/min:
- Apixaban: No specific dose reduction required for VTE treatment 1
- LMWH: Enoxaparin requires dose reduction to 1 mg/kg once daily for treatment and 30 mg once daily for prophylaxis 6
- Avoid: Rivaroxaban, edoxaban, and standard-dose LMWH are contraindicated 4
- Consider monitoring anti-Xa levels if using dalteparin (target 0.5-1.5 IU/mL) 6
CrCl 30-50 mL/min:
Elderly Patients (≥80 years)
- Apixaban: Dose reduction to 2.5 mg twice daily for atrial fibrillation if ≥80 years PLUS either weight ≤60 kg OR creatinine ≥1.5 mg/dL 1
- For VTE treatment: Standard dosing (10 mg→5 mg twice daily) is maintained regardless of age 1
- LMWH: Use with caution, particularly tinzaparin in patients ≥70 years with renal insufficiency (avoid due to increased mortality) 6
Low Body Weight (≤60 kg)
- Apixaban: Dose reduction to 2.5 mg twice daily for atrial fibrillation only if weight ≤60 kg PLUS either age ≥80 years OR creatinine ≥1.5 mg/dL 1
- For VTE treatment: No dose adjustment 1
- LMWH: Limited data; use caution with standard weight-based dosing 6
Obesity (BMI ≥40 kg/m² or weight >100 kg)
- Apixaban: No dose adjustment; standard fixed dosing is appropriate even with BMI >40 kg/m² 7
- LMWH:
Cancer-Associated VTE
For cancer-associated VTE, oral factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) are now preferred over LMWH for initial and long-term treatment. 10
- Apixaban: Standard dosing (10 mg→5 mg twice daily) is recommended 10
- Important caveat: For luminal GI malignancies, apixaban or LMWH may be preferred over rivaroxaban/edoxaban due to lower GI bleeding risk 10
- Extended prophylaxis: Low-dose apixaban 2.5 mg twice daily after initial treatment shows superior safety with similar efficacy compared to full-dose 11
- LMWH alternative: Dalteparin remains category 1 recommendation (200 IU/kg daily for 1 month, then 150 IU/kg daily) 4, 8
Common Pitfalls to Avoid
Do not bridge apixaban with parenteral anticoagulation when initiating VTE treatment—it is started immediately without LMWH overlap 4, 1
Do not confuse treatment doses with extended prophylaxis doses—apixaban 2.5 mg twice daily is only for extended prophylaxis after ≥6 months of treatment, not for acute VTE 1
Do not automatically reduce apixaban dose in elderly or low-weight patients for VTE treatment—dose reduction criteria apply primarily to atrial fibrillation indication 1
Do not use anti-Xa monitoring to guide LMWH dosing in obesity—use actual body weight-based dosing instead 5, 9
Avoid tinzaparin in elderly patients (≥70 years) with renal insufficiency due to increased mortality risk 6
For severe renal impairment (CrCl <30 mL/min), apixaban is preferred over LMWH due to lower renal clearance and no required dose adjustment 5, 12